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Abstract: Web-based prognostication tools may provide a simple and
economically feasible option to aid prognostication and selection of
chemotherapy in early breast cancers. We validated PREDICT, a free
online breast cancer prognostication and treatment benefit tool, in a
resource-limited setting.
All 1480 patients who underwent complete surgical treatment for
stages I to III breast cancer from 1998 to 2006 were identified from the
prospective breast cancer registry of UniversityMalayaMedical Centre,
Kuala Lumpur, Malaysia. Calibration was evaluated by comparing the
model-predicted overall survival (OS) with patients’ actual OS. Model
discrimination was tested using receiver-operating characteristic (ROC)
analysis.
Median age at diagnosis was 50 years. The median tumor size at
presentation was 3 cm and 54% of patients had lymph node-negative
disease. About 55% of women had estrogen receptor-positive breast
cancer. Overall, the model-predicted 5 and 10-year OS was 86.3% and
77.5%, respectively, whereas the observed 5 and 10-year OS was 87.6%
(difference:1.3%) and 74.2% (difference: 3.3%), respectively;P values
for goodness-of-fit testwere 0.18 and 0.12, respectively.The programwas
accurate in most subgroups of patients, but significantly overestimated
survival in patients aged <40 years, and in those receiving neoadjuvantar Yip, MD, Hele jen, MD, PhD,
irmala Bhoo-Pathy, MD, PhD
Based on its accurate performance in this study, PREDICT may be
clinically useful in prognosticating women with breast cancer and
personalizing breast cancer treatment in resource-limited settings.
(Medicine 94(8):e593)
Abbreviations: ER = estrogen receptor, HER2 = human epidermal
growth factor receptor, OS = overall survival, ROC = receiver-
operating characteristic, UMMC = University Malaya Medical
Centre.
INTRODUCTION
I n early breast cancers, accurate assessment of individualpatient prognosis is key to good clinical decision making.
At present, a number of prognostic prediction tools are available
either commercially or as free online programs to aid adjuvant
chemotherapy-related decision making.1 Oncotype-Dx2 and
Mammaprint,3 the 2 widely used commercial microarray gene
expression-based prognostic tests, are steadily gaining popu-
larity in Western oncology practices as powerful tools in risk
stratification, and selection and optimization of drug regimens
for women with early breast cancer.4 Nevertheless, these assays
are inaccessible for a vast majority of the global oncology
community, as they are expensive.5 A study in France had
recently demonstrated that Adjuvant! Online, a free, web-based
prognostic calculator, is far more cost effective than Mamma-
print.6 Furthermore, the clinical utility of multigene assays
remains unclear in Asian settings. In Asia, a substantial pro-
portion of women are diagnosed with estrogen receptor (ER)-
negative tumors, in part owing to the younger age at diagnosis of
breast cancer in the population.7–9 It has been previously shown
that almost half of the breast cancers in several Asian settings
including Hong Kong, Singapore, and India occurred in pre-
menopausal women7–9 and approximately 45% of patients had
ER-negative breast cancers.7,8
Online prognostication tools may therefore be valuable in
clinical practice and have been proposed to guide adjuvant
chemotherapy decision making, at institutional and even at
national levels in affluent countries (http://www.predict.nh-
s.uk/technical.html).10 Previous studies in the United States
and the Netherlands have shown that the use of prognostic
prediction tools were common among the oncologists.11,12 At
present, there are several free web-based prognostication pro-
grams to predict the survival of early breast cancer such as
Adjuvant! Online,13 PREDICT,14 and CancerMath.net.15 These
prognostic models have been validated in Western settings andess good calibration and discriminatory
ery few exceptions.12,21,22 However, a
dies conducted within multiethnic Asian
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patients with breast cancer had consistently shown that Adju-
vant! Online was overoptimistic in predicting survival.23–25 The
utility of PREDICT albeit remains unclear given that it has not
been validated in Asian settings.
PREDICT is a web-based prognostication tool, which
estimates the probability of survival for individual patients with
breast cancer and the impact of systemic treatment choices on
their survival probability (http://www.predict.nhs.uk/). Com-
pared with Adjuvant! Online, PREDICT uses an algorithm that,
additionally, includes mode of detection, human epidermal
growth factor receptor (HER2) status, as well as Ki67 status,
but does not include patient’s comorbidity. An advantage of
PREDICT is that it was developed for 2 end users, the clinicians
and the patients with breast cancer, involved in chemotherapy
decision making. The model was developed using a population-
based cancer registry in the United Kingdom, and externally
validated in a second United Kingdom-based registry and also a
large cohort of Canadian patients with breast cancer.18,19
Given that PREDICT is free, user friendly, and easily
accessible, it may provide an economically feasible option to
guide adjuvant chemotherapy decision making in resource-
limited settings. Malaysia is a middle-income country in South-
east Asia that comprises 3 major ethnic groups, that is, Malays,
Chinese, and Indians.26 The prognostic prediction performance
of PREDICT was assessed using a large hospital-based pro-
spective cohort of multiethnic patients with breast cancer in
Malaysia.
METHODS
This study obtained ethics approval from the Ethics Com-
mittee of the University Malaya Medical Centre (UMMC),
Kuala Lumpur, Malaysia. As the study relies on nonidentifiable
registry-based data, the need to obtain informed consent was
waived.
Study Participants
Data from the UMMC Breast Cancer Registry were used.
The UMMC is an academic tertiary hospital situated in the
relatively affluent part of Kuala Lumpur, Malaysia, and caters to
a predominantly middle-class urban population. The UMMC
Breast Cancer Registry is a prospective hospital-based registry
of consecutive women who were newly diagnosed with breast
cancer since 1993. Details of this registry have been described
elsewhere.7 The registry has been approved by the ethical
review committee of the institution and encompasses data on
patient’s demography (including age and ethnicity), tumor
characteristics (including pathological data on tumor size,
number of involved lymph nodes, tumor grade based on
Bloom–Scarff–Richardson classification, ER status, and
HER2 status based on immunohistochemistry testing), as well
as treatment. Treatment data include type of treatment (surgery,
chemotherapy, radiotherapy, and endocrine therapy), type of
surgery (mastectomy, breast-conserving surgery), chemother-
apy regimen, and type of endocrine therapy. Data on Ki67 status
were not available as it was not tested in a vast majority of
patients with breast cancer. Although data on use of trastuzumab
were also not available in this registry, its use in the hospital was
extremely low during the study period.
For this study, consecutive patients who were newly diag-
nosed with invasive nonmetastatic breast cancer from 1998,
Wong et alwhen second-generation (anthracycline-based) chemotherapy
was introduced in the hospital, until 2006, allowing at
least 5 years of follow-up (or until 2002, allowing 10 years
2 | www.md-journal.comof follow-up) were identified. Patients were included if they had
undergone complete surgical treatment (ie, mastectomy or
breast-conserving surgery followed by radiotherapy). We
excluded women with ER-positive tumors who did not receive
hormone therapy, and those with missing information on che-
motherapy regimen. Patients receiving first-generation che-
motherapy were also excluded given that first-generation
regimes were not included in PREDICT’s algorithm. The final
validation dataset for 5-year survival validation comprise 1480
women. For validation of 10-year survival, only 472 women
who were diagnosed until 2002 were included.
Follow-Up
In this study, the vital status of patients were obtained by
direct linkage with the National Registration Department in
Malaysia that has the mortality records of all Malaysians, using
patients’ unique identity card number. As passive follow-up was
done, we were able to follow-up all patients. Follow-up time
was calculated, starting at date of diagnosis with breast cancer
until death (all cause), or censored at the end of follow-up
(March 2013, date of linkage with national mortality registry).
Predicted 5 and 10-Year OS
For each patient, data on age (continuous), mode of
detection (screen detected, symptomatic, unknown), tumor size
(continuous), number of involved lymph nodes (continuous),
ER status (positive, negative, undefined), tumor grade (grade 1,
grade 2, grade 3, undefined), HER2 status (positive, negative,
undefined), Ki67 status (entered as undefined for all patients),
and adjuvant chemotherapy regimen (no chemotherapy, second-
generation chemotherapy, third-generation chemotherapy) were
manually entered. For every entry, the program predicted 5 and
10-year overall survival (OS) for 4 different scenarios, that is,
survival with no adjuvant treatment, benefit of adjuvant hor-
mone therapy, additional benefit of adding adjuvant chemother-
apy to adjuvant hormone therapy, and additional benefit of
adding trastuzumab to adjuvant chemotherapy and hormone
therapy. The survival probability corresponding to the actual
treatment received by the individual patient was recorded. For
instance, in the event a patient did not receive adjuvant che-
motherapy, the predicted OS for no adjuvant treatment will be
extracted from the output charts generated by PREDICT tool. In
order to ensure accuracy, all the PREDICT scores were calcu-
lated by 2 research personnel, and further audited by a third
person in a random sample of 10% of patients.
Statistical Analysis
Kaplan–Meier analysis was used to estimate the observed
5 and 10-year OS in the entire study population and within
subgroups. The predicted 5 and 10-year OS were derived from
the median of individual predicted survival probabilities from
PREDICT. To assess the calibration of the PREDICTmodel, the
observed and predicted 5 and 10-year OS rates were com-
pared.16,23 A x2 goodness-of-fit test was also performed to
assess the fit of PREDICT model.19 A P value of <0.05 for
this test was considered to represent a significant difference
between the observed and predicted mortality. Model cali-
bration was further assessed within strata of other prognostic
subgroups. The observed 5 and 10-year mortality estimates
were plotted against quintiles of predicted mortality.19
Medicine  Volume 94, Number 8, February 2015Receiver-operating characteristic (ROC) analysis was per-
formed to assess the discriminatory performance of PREDICT
(ie, its ability to discern patients having good prognosis—alive
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after 5 or 10 years—from those having poor prognosis—death
within 5 or 10 years).27,28 The area under the ROC curve (AUC)
gives an indication of the discriminatory performance of the
model, whereby it can be interpreted as the proportion of
patients who are correctly predicted to be alive or dead at
5 and 10 years. An AUC of 0.5 indicates no discriminative
performance whereas an AUC of 1.0 indicates perfect discrimi-
nation.
The National Institutes of Health Consensus Development
Conference recommends administration of adjuvant chemother-
apy for node-negative breast tumors when tumor size is >1 cm,
irrespective of hormone receptor status.29 Within this subgroup
of women, the accuracy of PREDICT was assessed. Sub-
sequently, the program was used to predict the OS benefit
conferred by chemotherapy in women in the above subgroup.
The utility of PREDICT is less clear in patients who have
received neoadjuvant chemotherapy, as the program per se does
not specify whether the model is suitable for use in this subset of
patients. Therefore, the performance of PREDICT within
women receiving neoadjuvant chemotherapy was also deter-
Medicine  Volume 94, Number 8, February 2015mined. The tumor size and lymph node status entered in















































FIGURE 1. Distribution of predicted (A) 5 and (B) 10-year overall su
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.P values of<0.05 were considered statistically significant.
Analyses were performed using SPSS for Window version 20.0
(SPSS Inc., Chicago, IL).
RESULTS
In this cohort of Asian women with early breast cancer, the
median age at diagnosis was 50 years (quartile 1: 44 years,
quartile 3: 58 years). A large proportion was Chinese (n¼ 994,
67%), followed by Malays (n¼ 281, 19%), Indians (n¼ 192,
13%), and other races (n¼ 13, 1%). A vast majority of patients
were symptomatic at presentation (n¼ 1421, 96%), whereas
only 4% of women in this study had mammographic screening-
detected breast cancer.
The median tumor size at presentation was 3 cm (quartile
1: 2 cm, quartile 3: 4 cm), and 663 patients had lymph node
involvement (46%). Data on ER and HER2 status were not
available in 47 and 179 patients, respectively, whereas tumor
grade was unknown in 259 women. Within patients with
available information, ER and HER2 were expressed in
Performance of PREDICT in Asian Womenapproximately 771 (54%) and 496 (38%) patients, respectively,
whereas 484 (40%) patients had high-grade tumors. Among
1054 patients who received adjuvant chemotherapy, 17 patients
PREDICT score











rvival in Asian women with early breast cancer by PREDICT tool.
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(1.6%) did not complete their chemotherapy cycles. Only 38
women (4%) had received taxane-based (third-generation)
regimes, whereas 1016 women received anthracycline-based
(second-generation) regimes. A majority of patients who
received endocrine therapy were given tamoxifen, whereas
25 received aromatase inhibitors and 20 received tamoxifen
followed by aromatase inhibitors.
Figure 1 shows the distribution of the predicted 5 and
10-year OS as estimated by PREDICT in our patients. Although
most patients had high predicted 5 and 10-year OS, a smaller
number of women were predicted to have low OS. As the
predicted scores were negatively skewed, we reported the
median score.
In patients with ER-positive breast cancers, endocrine
therapy was estimated to confer an additional survival benefit
of 2.6% and 5.3% in 5 and 10 years, respectively. Adminis-
tration of adjuvant chemotherapy in this group of women was
predicted to provide an additional OS benefit of 1.7% and 3.7%
at 5 and 10 years, respectively. Among patients with ER-
negative breast cancers, the program predicted that adjuvant
chemotherapy would confer an additional OS benefit of 9.5%
and 11.3% at 5 and 10 years, respectively.
Wong et alAlthough PREDICT tool had predicted that of 1480
patients with complete follow-up of 5 years, 203 would have




































FIGURE 2. Calibration plot of observed mortality with 95% confidenc
value, at (A) 5 and (B) 10 years after diagnosis.
4 | www.md-journal.comcomplete follow-up of 10 years, the predicted number of deaths
was 106, whereas in reality, a total of 122 deaths were observed.
Overall, PREDICT was accurate in predicting short-term
survival; the predicted 5-year OS was 86.3% versus the actual
observed 5-year OS that was 87.6% (difference: 1.3%). The
P value for goodness-of-fit test was 0.18. However, the tool
slightly overestimated long-term survival; the predicted 10-year
OS was 77.5% whereas the observed 10-year OS was 74.2%
(difference: 3.3%). The corresponding P value for goodness-of-
fit test for 10-year OS was 0.12. The program seems to have
performed fairly well in patients with good prognosis and only
displayed overoptimism in patients with the poorest prognosis
(lowest quintile) (Figure 2).
PREDICT was also accurate in most subgroups of patients,
except in several subgroups wherein a tendency of the program
to be overoptimistic was noted (Tables 1 and 2). For instance, in
women aged <40 years, 5-year OS was overestimated by 6.8%
whereas 10-year OS was overestimated by 17.2%. The program
also seems to be overoptimistic in predicting 10-year OS in
Malay patients, with a difference of about 10% (P¼ 0.06).
Although the model seems to have underestimated short-term
survival in patients with ER-negative tumors, the underestima-
Medicine  Volume 94, Number 8, February 2015tion was not seen in prediction of long-term survival. Analysis
based on HER2 status, however, yielded conflicting results







60 80 100 120
40 50 60 70
e interval against predicted mortality by quintiles of the predicted
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.









(Predicted  Observed) P Valuez
All patients 1480 (100) 87.6 (85.8–89.4) 86.3 1.3 0.18
Age, y
<40 0187 (12.6) 81.3 (75.6–87.0) 88.1 6.8 <0.001
40–64.9 1104 (74.6) 89.2 (87.4–91.0) 87.1 2.1 0.05
65 0189 (12.8) 84.1 (82.7–85.8) 81.3 2.8 0.40
Ethnicity§
Chinese 0994 (67.2) 89.7 (87.7–91.6) 88.1 1.6 0.14
Malay 0281 (19.0) 84.0 (79.7–88.3) 81.8 2.2 0.40
Indian 0192 (13.0) 81.8 (76.4–87.2) 81.9 0.1 <0.001
Tumor size, cm
<2 313 (21.1) 96.5 (94.5–98.5) 94.6 1.9 0.73
2.0–5.0 926 (62.6) 88.6 (86.7–90.6) 84.1 4.5 0.14
>5 241 (16.3) 72.2 (66.5–77.9) 70.1 2.1 0.70
Lymph node involvementjj
No 776 (53.9) 94.6 (93.0–96.2) 91.4 3.2 <0.001
Yes 663 (46.1) 79.9 (76.8–82.7) 75.6 4.3 0.02
Estrogen receptor status
Negative 662 (46.2) 81.9 (79.0–84.8) 75.9 6.0 <0.001
Positive 0771 (53.8) 92.1 (90.1–94.1) 92.6 0.5 0.60
HER2 receptor status
Negative 0805 (61.9) 87.7 (85.3–90.1) 88.7 1.0 0.40
Positive 0 496 (38.1) 86.3 (83.4–89.2) 79.7 6.6 <0.001
Grade
Low 133 (10.9) 97.0 (94.1–99.9) 95.9 1.1 0.65
Moderate 604 (49.5) 89.9 (87.5–92.3) 89.5 0.4 0.80
High 484 (39.6) 80.0 (76.5–83.5) 75.1 4.9 0.03
Unknown 259 91.5 (88.2–94.8) 89.5 2.0 0.34
Neoadjuvant chemotherapy
No 1359 (91.8) 89.3 (87.7–90.9) 87.2 2.1 0.03
Yes 0121 (8.2) 68.6 (60.4–76.8) 74.4 5.8 0.21
CI ¼ confidence interval, HER2 ¼ human epidermal growth factor receptor.
Using median predicted 5-year overall survival by PREDICT.
yBased on difference between the predicted overall survival and observed overall survival.
zDerived from x2 goodness-of-fit test comparing predicted and observed mortality estimates.
§ Excluding 13 patients from other races.
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Medicine  Volume 94, Number 8, February 2015 Performance of PREDICT in Asian WomenWithin patients with node-negative tumors measuring
>1 cm, PREDICT was accurate whereby the predicted 5 and
10-year OSs were 90.3% and 82.0%, respectively, whereas the
observed 5 and 10-year OSs were 93.3% (95% confidence
interval [CI]: 92.5–96.1) and 82.2% (95% CI: 76.5–87.9),
respectively. Within this subset of patients, the program had
predicted that adjuvant chemotherapy would only confer an
additional survival benefit of 1.2% at 5 years, and 3.0% at
10 years irrespective of hormonal receptor status.
It was found that PREDICT was persistently overoptimis-
tic in predicting both short-term and long-term OS among
patients who had received neoadjuvant chemotherapy, by
approximately 6% (Tables 1 and 2).
The ROC analysis of PREDICT showed that the model
Excluding 41 patients with missing data on lymph node involveme
Excluding 47 patients with unknown estrogen receptor status.discriminated good and poor survivors fairly well, with an AUC
of 0.78 (95% CI: 0.74–0.81) and 0.73 (95% CI: 0.68–0.78) for
5 and 10-year survival, respectively.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.DISCUSSION
Within this large cohort of women with early-stage breast
cancer from a middle-income setting, PREDICT performed
well in terms of calibration and discrimination. However,
PREDICT substantially overestimated survival in very young
patients with breast cancer, as well as in patients who have
received neoadjuvant chemotherapy.
The current finding that PREDICT is accurate in predicting
OS in early breast cancers and performs robustly across a
majority of patient subgroups suggest that the program may
be clinically useful in similar Asian settings. It is felt that the
program can safely be used to refrain chemotherapy adminis-
tration in patients demonstrating low survival benefit from
adjuvant chemotherapy. For instance, the National Institutes
of Health Consensus Development Conference had recom-
mended administration of adjuvant chemotherapy for node-
negative breast tumors when tumor size is >1 cm, irrespective
www.md-journal.com | 5








(Predicted  Observed)y P Valuez
All patients 472 (100) 74.2 (70.3–78.1) 77.5 3.3 0.12
Age, y
<40 071 (15.0) 66.2 (55.2–77.2) 83.4 17.2 <0.01
40–64.9 361 (76.5) 75.9 (71.4–80.4) 77.5 1.6 0.51
65 40 (8.5) 72.5 (58.6–86.4) 61.1 11.4 0.25
Ethnicity§
Chinese 314 (66.5) 79.0 (74.5–83.5) 79.8 0.8 0.71
Malay 097 (20.6) 59.8 (50.0–69.6) 69.9 10.1 0.06
Indian 056 (11.9) 71.4 (59.6–83.2) 69.8 1.6 0.81
Tumor size, cm
<2 135 (28.6) 90.4 (85.5–95.3) 88.9 1.5 0.61
2.0–2.9 84 (17.8) 70.2 (60.4–80.0) 80.1 9.9 0.05
>5 080 (16.9) 50.0 (39.0–61.0) 52.9 2.9 0.75
Lymph node involvementjj
No 243 (53.4) 84.8 (80.3–89.3) 85.6 0.8 0.74
Yes 212 (46.6) 62.3 (55.8–68.8) 64.8 2.5 0.56
Estrogen receptor status
Negative 191 (43.3) 63.4 (56.5–70.3) 65.8 2.4 0.53
Positive 250 (56.7) 81.6 (76.7–86.5) 84.1 2.5 0.34
HER2 receptor status
Negative 130 (36.7) 70.8 (63.0–78.6) 80.7 9.9 <0.01
Positive 224 (63.3) 71.0 (65.1–76.9) 72.4 1.4 0.70
Grade
Low 049 (12.6) 98.0 (94.1–100) 91.4 6.6 0.13
Moderate 195 (50.3) 76.4 (70.5–82.3) 79.9 3.5 0.26
High 144 (37.1) 63.9 (56.1–71.7) 60.9 3.0 0.59
Unknown 084 72.6 (63.0–82.2) 81.6 9.0 0.04
Neoadjuvant chemotherapy
No 418 (88.6) 76.8 (72.7–80.9) 78.4 1.6 0.46
Yes 054 (11.4) 53.7 (40.4–67.0) 60.2 6.5 0.38
CI ¼ confidence interval, HER2 ¼ human epidermal growth factor receptor.
Using median predicted 5-year overall survival by PREDICT.
yBased on difference between the predicted overall survival and observed overall survival.
zDerived from x2 goodness-of-fit test comparing predicted and observed mortality estimates.
§ Excluding 3 patients from other races.
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Wong et al Medicine  Volume 94, Number 8, February 2015of hormone receptor status.29 However, in this subset of patients
within the current study, PREDICT had predicted that the
additional OS benefit conferred by adjuvant chemotherapy at
10 years was only 3%, underscoring the importance of tailoring
treatment approaches based on individual patient prognoses.
Nevertheless, the margin of benefit that is deemed appropriate
for decision-making is arbitrary and depends on individual
physicians and patients. The Cambridge Breast Unit (United
Kingdom), for instance, uses the absolute 10-year survival
benefit from chemotherapy to guide decision making for adju-
vant chemotherapy; no chemotherapy if <3%; chemotherapy
discussed as a possible option if 3% to 5%; and chemotherapy
recommended if >5%.18
Based on the current findings, PREDICT is not recom-
Excluding 17 patients with missing data on lymph node involveme
Excluding 31 patients with unknown estrogen receptor status.mended for use in very young Asian women with breast cancer.
A common weakness shared between PREDICT and Adjuvant!
Online is that both models poorly performed in very young
6 | www.md-journal.compatients, not only in Asians but also in whites.16–18,23 Patients
diagnosed with breast cancer at a very young age have poor
survival,30–32 and the current variables included in the PRE-
DICT algorithm seem unable to adequately prognosticate this
subgroup of patients.
In this study, PREDICT marginally overestimated 10-year
OS by about 3%. A previous validation study of Adjuvant!
Online within our setting had shown that the model was
generally overoptimistic across most subgroups of patients,
whereby the 10-year OS was overestimated by approximately
7% (95% CI: 3.0–10.4).22 These results, taken together with the
accurate performance of PREDICT in predicting 5-year OS,
seem to suggest that systematic differences in background
mortality (including comorbidities), between our study popu-
lation and populations where the above models were developed
(ie, United Kingdom and United States), are more likely to
play a central role in explaining the overoptimism pertaining
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
to long-term survival predictions. For instance, life expectancy
in 2010 for a female at 50 years of age in Malaysia was 78.4
years, whereas in the United Kingdom and United States, it was
83.9 and 83.1 years, respectively (http://www.worldlifeexpec-
tancy.com/world-healthrankings).
Nevertheless, differences in lifestyle after breast cancer
between the Western and Asian populations may also explain
disparities in long-term survival.33 This is in view that studies
from other high-income Asian settings such as Korea and
Taiwan have also shown that Western-derived long-term sur-
vival prediction models may still be overoptimistic in Asian
populations.24,25 Differences in life expectancy and lifestyle
after diagnosis of breast cancer may also explain the over-
optimism of PREDICT in predicting long-term survival among
patients of Malay ethnicity.23,34
Although information on HER2 status was available, the
testing was not routine prior to 2005 in UMMC and was highly
selective, whereby patients with the highest and lowest baseline
prognosis were not tested.35 This may explain the conflicting
results based on HER2 status in the current study. We are
uncertain of the influence of lack of data on Ki67 status on our
results, given that the model was still largely able to accurately
prognosticate our patients with breast cancer. Although PRE-
DICT was recently adapted to include Ki67 status in its
algorithm, it is important to note that the added prognostic
value of Ki67 is yet to be externally validated due to lack of
appropriate populations (http://www.predict.nhs.uk/techni-
cal.shtml). Furthermore, there is a general lack of clarity in
standardizing assessment of these factors for routine clinical
practice, particularly in determining optimal cutoff values to
establish Ki67 status.36 It is also acknowledged that the number
of patients in some subgroup analyses were relatively small,
which may have resulted in unstable estimates.
Furthermore, an inherent issue with PREDICT is that the
model does not include patient’s comorbidity. This maybe
problematic in multiethnic Asian women given that Asian
populations have been found to have higher risk of cardiovas-
cular diseases compared with their white counterparts.37 Con-
sidering that breast cancer therapy, particularly radiotherapy,
chemotherapy, and HER2-targeting therapy, may be associated
with cardiac toxicity,38 it may be necessary that PREDICT is
optimized to take into account the baseline cardiovascular risk
profiles of Asian patients. This may be done using newer
sophisticated techniques such as artificial neural networks
and machine learning.39–41
Online breast cancer prognostic prediction tools may play
a valuable role in clinical practice to aid chemotherapy-related
decision making as they are more cost effective than molecular
profiling.6 Although previous studies, which validated Adju-
vant! Online, consistently showed that the program is over-
optimistic in middle and high-income Asian settings, the current
validation exercise of PREDICT reaffirms thatWestern-derived
prognostic scoring systems may still be relevant and applicable
in Asian patients. Nevertheless, it is important to note that
validation of such tools are extremely crucial and a prerequisite
for adoption into clinical practices in other settings.
In conclusion, PREDICT possesses appreciable clinical
utility in resource-limited settings. The program may poten-
tially serve as a clinical decision aid for both patients with breast
cancer and physicians in therapeutic decision making. How-
ever, PREDICT may not be suitable for use in very young
Medicine  Volume 94, Number 8, February 2015patients (ie, <40 years at diagnosis), and patients who have
received neoadjuvant chemotherapy. Future studies are required
to optimize the model in Asian settings by inclusion of data on
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.comorbidities and assess the impact of using PREDICT on
multidisciplinary tumor board decisions. It is also pertinent to
determine the usefulness of the program to patients, in under-
standing their prognoses and helping them make adjuvant
treatment-related decisions.1
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